Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

toothbrush

- PMLiVE

AbbVie’s Elahere shows consistent survival benefits in late-stage ovarian cancer trial

Approximately 20,000 cases of the disease are diagnosed in the US every year

- PMLiVE

Novo shares phase 3 results for obesity candidate CagriSema in diabetes patients

The company is expecting to file for the first regulatory approval of the drug next year

- PMLiVE

Breaking down the barriers

Liberating omnichannel’s full potential

- PMLiVE

AstraZeneca to expand cell therapy capabilities with $1bn EsoBiotec acquisition

The biotech’s ENaBL platform enables cell therapies to be administered through an IV injection

- PMLiVE

NICE recommends Pharming’s Joenja as first treatment for ultra-rare immune disease APDS

Approximately 40 to 50 people in the UK are known to be living with the inherited disorder

- PMLiVE

Boehringer Ingelheim and Salipro Biotech enter drug development partnership

The companies will focus on targeting proteins in areas such as cardio-renal-metabolic diseases

- PMLiVE

Communicating value to US Payers: Insights for Pharma and Medtech

What do global market access teams need to know about the US market? What do US payers expect to hear from Pharma and Medtech companies? What kind of value messaging...

Petauri Evidence

- PMLiVE

The abolition of NHS England: Navigating NHS restructuring and its impact on the pharmaceutical industry

Last week Prime Minister Sir Keir Starmer announced the abolition of NHS England to "cut bureaucracy" and bring management of the health service "back into democratic control". This significant change...

Petauri Evidence

Innovative Trials celebrates its 15th anniversary

🎉 Cheers to 15 years of patient recruitment and retention innovation and impact at Innovative Trials! 🎉 From 2010 to 2025, we’ve been on an incredible journey of growth, impact,...

Innovative Trials

- PMLiVE

Bristol Myers Squibb granted EC approval for Breyanzi in follicular lymphoma

The disease accounts for up to 30% of non-Hodgkin lymphoma cases

- PMLiVE

Roche to launch new innovation centre at Harvard’s Enterprise Research Campus

The first phase of construction on the ERC is expected to be complete in 2026

- PMLiVE

Amgen’s Uplizna shows promise in phase 3 generalised myasthenia gravis study

Regulatory submissions are expected to be complete in the first half of this year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links